← Therapy pipeline
Investigational · Obesity development

Petrelintide

Zealand Pharma / Roche

Long-acting amylin analogue studied alone and as a combination partner.

amylin
Other study areas
Type 2 diabetesCardiovascular outcomes
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 3Updated as of November 2026
SponsorZealand Pharma / Roche
Targetsamylin
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Selected study results

ZUPREME-2 · primary endpointMean body-weight change · primary endpointBody weight decreased 9.2% · 28 weeks · Phase 2
Phase 2 · Injection · Sponsor-reported Phase 2 topline

Mean body-weight change · primary endpoint · 28 weeks

Study focus: Weight management with type 2 diabetes

Up to 9.2% mean weight reduction versus 2.0% with placebo at week 28 (7.4%–9.2% across treatment arms).

Petrelintide (maximum across three dose arms)
9.2%
Placebo
2%

Adults with overweight or obesity and type 2 diabetes · Once-weekly subcutaneous petrelintide (three dose arms) · Trial N=220 · Efficacy estimand; treatment-arm range 7.4%–9.2%. Results & methods ↗

The announcement does not map the maximum result to a specific dose; full results are expected at an upcoming scientific conference. Mean baseline BMI was 36.3 kg/m² and mean HbA1c was 8.0%.

ZUPREME-1 · primary endpointMean body-weight change · primary endpointBody weight decreased 9.8% · 28 weeks · Phase 2
Phase 2 · Injection · Peer-reviewed numerical results

Mean body-weight change · primary endpoint · 28 weeks

Study focus: Weight management without type 2 diabetes

Petrelintide 5 mg
9.8%
Placebo
1.7%

Adults with overweight or obesity without type 2 diabetes; 485 received at least one dose · Once-weekly injection · Trial N=493 · Efficacy estimand; published randomized Phase 2 study. Results & methods ↗ · Publication ↗

Same trial · week-28 efficacy estimand
Weekly doseWeight change
1 mg−7.9%
2.5 mg−7.9%
5 mg−9.8%
7 mg−9.3%
9 mg−9.4%
Placebo−1.7%

The primary endpoint is week 28. Week-42 secondary results use separately labeled analyses; the abstract does not resolve all week-42 dose mappings.

ZUPREME-1Mean body-weight change · week-42 secondary endpointBody weight decreased 10.2% · 42 weeks · Phase 2
Phase 2 · Injection · Published trial; numbers from sponsor report

Mean body-weight change · week-42 secondary endpoint · 42 weeks

Study focus: Weight management without type 2 diabetes

Up to 10.2% mean weight reduction at 42 weeks, versus 1.4% with placebo.

Investigational regimen
10.2%
Placebo / comparator
1.4%

Adults with overweight or obesity without type 2 diabetes · Dose group with the largest reported reduction vs placebo; dose not specified in the cited release · Trial N=493 · Treatment-policy estimand; maximum dose-group result reported by sponsor. Results & methods ↗ · Publication ↗

Additional results or analyses from this same study
  • Same trial · efficacy estimandUp to 10.7% mean weight reduction versus 1.7% with placebo at week 42, using the efficacy estimand. Maximum results from different analyses should not be assumed to be the same dose group.

493 participants were randomized; 485 received at least one dose. Week 42 is secondary. The sponsor reports the maximum treatment-policy dose-group result without identifying the dose; week-42 efficacy dose mapping remains unverified.

ZUPREME-2 · HbA1c outcomeHbA1c changeHbA1c decreased 0.65 percentage points · 28 weeks · Phase 2
Phase 2 · Injection · Sponsor-reported Phase 2 topline

HbA1c change · 28 weeks

Study focus: Weight management with type 2 diabetes

HbA1c decreased by up to 0.65 percentage points; placebo increased by 0.23.

Petrelintide (maximum)
0.7 percentage points
Placebo
0.2 percentage points increase

Adults with overweight or obesity and type 2 diabetes · Once-weekly subcutaneous petrelintide (three dose arms) · Trial N=220 · Efficacy estimand; placebo-adjusted reduction 0.61–0.88 percentage points across arms. Results & methods ↗

Full results are expected at an upcoming scientific conference. Participants were receiving metformin with or without an SGLT2 inhibitor; mean baseline HbA1c was 8.0%. Gastrointestinal-event discontinuation was 1.9% with petrelintide versus 1.7% with placebo.

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

Tolerability

Safety context

In Zealand's June report, nausea occurred in 19.6% of petrelintide recipients versus 6.2% with placebo; vomiting occurred in 3.0% versus 6.2%. The September announcement described no vomiting or gastrointestinal-related discontinuation in the maximally effective dose group. In ZUPREME-2 (n=220), the sponsor reported no unexpected safety signals and said the most frequent adverse events were gastrointestinal-related, mostly mild during escalation; discontinuation due to gastrointestinal events was 1.9% with petrelintide versus 1.7% with placebo. Full ZUPREME-2 safety results are pending.

02 / How it works

Mechanism at a glance

GLP-1GLP-1—
GIPGIP—
GCGglucagon—
AMYamylinTargeted
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

InjectionOnce weekly
Phase 3ZUPREME initiated
Milestone → next

Latest: ZUPREME-1 Phase 2 results are published in The Lancet Diabetes & Endocrinology. On October 7, 2026, Zealand reported positive ZUPREME-2 Phase 2 topline results; the registrational Phase 3 ZUPREME program has started, with first participants initiating treatment.

Next: Full ZUPREME-2 results and Phase 3 monotherapy outcomes are pending. Zealand announced initiation of the separate Phase 2 ZYNERGY combination study with enicepatide on November 18, 2026.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 3 studies3 records

Phase 3

ZUPREME-3

Weight management
Study: RecruitingResults: No registry results posted yetStatus reviewed November 2026

Adults with overweight or obesity without type 2 diabetes; global placebo-controlled registrational study.

Phase 3

ZUPREME-4

Weight management with type 2 diabetes
Study: RecruitingResults: No registry results posted yetStatus reviewed November 2026

Adults with overweight or obesity and type 2 diabetes; global placebo-controlled registrational study.

Phase 3

ZUPREME-5

Weight management with cardiovascular disease
Study: RecruitingResults: No registry results posted yetStatus reviewed November 2026

Adults with overweight or obesity and established cardiovascular disease; global placebo-controlled registrational study.

Phase 2 studies2 records

Phase 2

ZUPREME-1

Weight management
Study: CompletedResults: Peer-reviewed primary endpoint and separate sponsor week-42 resultsStatus reviewed November 2026

Dose-ranging monotherapy study in adults with obesity or overweight and a weight-related complication; Phase 2 topline reported.

Phase 2

ZUPREME-2

Weight management with type 2 diabetes
Study: CompletedResults: No registry results posted yetStatus reviewed November 2026

Monotherapy study in adults with obesity or overweight and type 2 diabetes.